3Tuteja S,Alloway RR,Johnson JA,et al.The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients.Transplantation,2001,71(9):1303-1307.
4Kuypers DR,Clases K,Evenepoel P,et al.Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids:a prospective sundy in one hundred de novo renal transplant recipients.Clin Pharmacokinet,2004,43(11):741-762.
5Abu-Elmagd K,Fung JJ,Alessiani M,et al.The effect of graft function on FK506 plasma levels,dosages,and renal function,with particular reference to the liver.Transplantation,1991,52 (1):71-77.
6Mahalati K,Belitsky P,Kiberd B,et al.Absorption profiling:a novel method for monitoring neoral in kidney transplantation that reduces rejection and nephrotoxicity.Transplatation,2000,69:110-118.
8Dai Y,Hebert MF,Isoherranen W,et al.Effect of polymorphism on tacrolimsms metabolic clearance in vitro[J].Drug Metab Dispos,2006,34(5):836-847.
9Katsakiori PF,Papapetrou EP,SakeUaropoulos GC,et al.Factors affecting the long-term response to tacrolimus in renal transplant patients:pharmacokinetic and pharmacogenetic approach[J].Int J Med Sci,2010,7(2):94-100.
10Roy JN,Barama A,Poirier C,et al.Cyp3A4,Cyp3A5 and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients[J].Pharmaeogenetics and Genomics,2006,16(9):659-665.
